Myriagon develops effective, non-addictive, oral analgesics for neuropathic pain. We have discovered a novel analgesic for chemotherapy induced peripheral neuropathy (CIPN). CIPN is a debilitating side effect of chemotherapy and symptoms include burning sensations and unbearable pain. CIPN is the major cause for dose-reduction and discontinuation of chemotherapy. To make matters worse, ~30% of patients that received chemotherapy experience chronic CIPN symptoms. Currently, there are no approved drugs for CIPN and patients reside to off-label use of various drug classes, including opioids. Unfortunately, these treatment options provide only limited pain relief and cause serious side effects including physical dependence. At Myriagon we aim to resolve this critical unmet medical need for safe and effective analgesics.

We have discovered and patented peripherally restricted monoacylglycerol lipase (MAGL) inhibitors. In animal models for CIPN, oral administration of our lead compound induces full pain relief without physical dependence. Our MAGL inhibitor harnesses anti-inflammatory mechanisms which gives opportunities beyond CIPN to other types of pain and inflammation. To support this, we have demonstrated efficacy in multiple models of pain and inflammation. Therefore, we believe Myriagon’s MAGL inhibitor has the potential to become the most effective non-steroidal anti-inflammatory analgesic on the market.